Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, R.O.C.
School of Public Health, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Aging (Albany NY). 2022 Apr 22;14(8):3484-3528. doi: 10.18632/aging.204026.
Previous meta-analyses only examined the association between single gene polymorphisms and osteoporosis; there is no compilation of all gene loci that correlate with osteoporosis in the literature. In this study, we develop a new literature-based approach, a decisive gene strategy (DGS), to examine the sufficiency of the cumulative sample size for each gene locus and to assess whether a definite conclusion of the association between the gene locus and osteoporosis can be drawn.
The DGS was used to search PubMed, Embase, and Cochrane databases for all meta-analyses that correlated gene polymorphisms with osteoporosis. Trial sequential analysis was employed to examine the sufficiency of the cumulative sample size. Finally, we assessed the importance of gene loci in osteoporosis based on whether there were enough sample sizes and the heterogeneity of the literature with the I value.
After excluding 169 irrelevant publications, 39 meta-analysis papers were obtained. Among Caucasians, in 17 gene loci, there were eight gene loci (e.g., vitamin D Receptor ApaI rs7975232) with sufficient cumulative sample size to confirm that they were unrelated to the disease. Among Asians, in 15 gene loci, four gene loci that had sufficient sample sizes were risk factors: VDR FokI rs2228570 (odds ratio (OR) = 1.44, 95% confidence interval (CI) = 1.22-1.70), TGF β1 rs1800470 (OR = 1.35, 95% CI = 1.10-1.65), IGF1 rs2288377 (OR = 1.44, 95% CI = 1.28-1.62), and IGF1 rs35767 (OR = 1.20, 95% CI = 1.06-1.36), respectively, whereas one gene locus, ESR2 RsaI rs1256049 (OR = 0.69, 95% CI = 0.59-0.81), was a protective factor.
The DGS successfully identified five gene loci in osteoporosis that will apply to other diseases to find causal genes, which may contribute to further genetic therapy.
之前的荟萃分析仅研究了单一基因多态性与骨质疏松症之间的关联;目前还没有文献汇总与骨质疏松症相关的所有基因座。本研究我们开发了一种新的基于文献的方法,即决定性基因策略(DGS),以检查每个基因座的累积样本量是否充足,并评估是否可以得出该基因座与骨质疏松症之间关联的明确结论。
DGS 用于搜索 PubMed、Embase 和 Cochrane 数据库中与基因多态性与骨质疏松症相关的所有荟萃分析。采用试验序贯分析来检查累积样本量是否充足。最后,我们根据是否有足够的样本量以及文献的异质性,用 I 值来评估基因座在骨质疏松症中的重要性。
排除 169 篇不相关的文献后,获得了 39 篇荟萃分析论文。在白种人中,在 17 个基因座中,有 8 个基因座(如维生素 D 受体 ApaI rs7975232)具有足够的累积样本量,可以确定它们与疾病无关。在亚洲人中,在 15 个基因座中,有 4 个基因座具有足够的样本量是危险因素:VDR FokI rs2228570(比值比(OR)=1.44,95%置信区间(CI)=1.22-1.70),TGF β1 rs1800470(OR=1.35,95% CI=1.10-1.65),IGF1 rs2288377(OR=1.44,95% CI=1.28-1.62)和 IGF1 rs35767(OR=1.20,95% CI=1.06-1.36),而一个基因座 ESR2 RsaI rs1256049(OR=0.69,95% CI=0.59-0.81)是保护因素。
DGS 成功确定了骨质疏松症中的 5 个基因座,这将适用于其他疾病以寻找因果基因,这可能有助于进一步的遗传治疗。